Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma

Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More